Pursuing Board Changes to Restore Investor Confidence and Ensure Integrity of Ongoing Sale Process Broadwood Seeks to Remove the Directors Most Responsible...
Third-quarter 2025 sales of $2.6 billion, up 6% on a reported basis, or up 5% constant currency 1 (cc), versus third-quarter 2024 ...
Believes New, Independent, and Experienced Directors Are Needed in Order to Restore Trust in the Board and Confidence in the Go-Shop Process Notes Recently...
Monday (NOTE: Some economic figures from the States may be delayed this week due to the U.S. government ...
Reminds STAAR’s Board That It Does Not Need Alcon’s Permission to Remain Independent or Run a Proper Strategic Alternatives Process
Alcon (SIX/NYSE: ALC), the global leader in eye care, today announced that it has filed an investor presentation in support of the proposed acquisition of STAAR Surgical Company (NASDAQ: STAA) with the...
Appalled that STAAR’s Board Reneged on Its Promise to Let Shareholders Decide the Fate of the Proposed Transaction in a Timely Manner Urges STAAR to...
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ: STAA), the manufacturer of the Implantable Collamer® Lens (ICL), today...
Leading Proxy Advisory Firms ISS, Glass Lewis, and Egan-Jones, as well as Long-Term Shareholders Echo Broadwood’s Concerns over Deeply Deficient Sale Process, Timing, and Price ...
Calls on Board to Avoid Temptation to Delay Meeting or Further Mislead Shareholders Broadwood Continues to Urge Shareholders to Vote “ ...